AKD Pharma Declares First Human Trial of Personality Transition System a
Success

Tuesday January 10th, 2175 - 1:04pm PST

By Jaqueline Craig

SAN FRANCISCO, CA (Associated Correspondence/FinanceWire) - AKD Pharma
CEO Alexy Dimitry announced at a press conference today the first
successful transplantation of a human personality to a cloned target body.
This was the culmination of almost a quarter century of effort and an
estimated half trillion new dollars of research and development funds.

Following the press conference, a company spokesperson remained to answer
questions about the technology which they have dubbed "Personality
Transition" or PT for short. Mrs. Du Pre explained that they basically
freeze the personality to be transitioned in place at a quantum level.
Using technology licensed from the government's teleportation project,
they unobserve the personality at the quantum level and reobserve it onto
a clone specially prepared for the procedure. She noted that there is a
period of time when the transplanted personalities goes through a
readjustment phase where they experience a bit of dizziness and
disorientation. This appears to be a side effect of getting used to a
different body, no matter how familiar the target clone's DNA is.

The test subject, a 94 year old man suffering from rare, incurable form of
acute arteriosclerosis had his personality implanted onto a clone
constructed from his own DNA and artificially aged to be 28 years old.
When asked about how the experience felt the test subject, one Martin
Canner, noted "Well, it was a bit weird at first, I stumbled a lot, but I
can tell you that being in a younger body is exhilarating. I haven't felt
this good in, well, I guess 60 years!"